Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

MILAN — When added to prostate biopsy, gallium-68 prostate-specific membrane antigen (PSMA)-PET/CT improves detection of clinically significant prostate tumors and helps guide treatment planning, new ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...